Marie Thibault
Stock Analyst at BTIG
(4.04)
# 570
Out of 4,993 analysts
80
Total ratings
54.05%
Success rate
12.43%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Reiterates: Buy | $127 | $98.03 | +29.55% | 11 | Sep 23, 2025 | |
| MASI Masimo | Reiterates: Buy | $198 | $139.05 | +42.39% | 4 | Sep 11, 2025 | |
| EMBC Embecta | Reiterates: Buy | $25 | $13.66 | +83.02% | 3 | Sep 5, 2025 | |
| OBIO Orchestra BioMed Holdings | Downgrades: Neutral | n/a | $2.40 | - | 2 | Aug 20, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $148 → $145 | $133.45 | +8.65% | 12 | Jul 18, 2025 | |
| ATRC AtriCure | Maintains: Buy | $58 → $52 | $34.94 | +48.83% | 7 | Apr 30, 2025 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $322.25 | -16.21% | 4 | Nov 8, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $38.25 | +69.93% | 8 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $47.47 | +135.94% | 1 | Sep 10, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $68.35 | +75.57% | 7 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.37 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.33 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $10.85 | +84.42% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $171.60 | -18.41% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.68 | +317.91% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.68 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.46 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $294.25 | -97.96% | 1 | Apr 9, 2020 |
Boston Scientific
Sep 23, 2025
Reiterates: Buy
Price Target: $127
Current: $98.03
Upside: +29.55%
Masimo
Sep 11, 2025
Reiterates: Buy
Price Target: $198
Current: $139.05
Upside: +42.39%
Embecta
Sep 5, 2025
Reiterates: Buy
Price Target: $25
Current: $13.66
Upside: +83.02%
Orchestra BioMed Holdings
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.40
Upside: -
Abbott Laboratories
Jul 18, 2025
Maintains: Buy
Price Target: $148 → $145
Current: $133.45
Upside: +8.65%
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $58 → $52
Current: $34.94
Upside: +48.83%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $322.25
Upside: -16.21%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $38.25
Upside: +69.93%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $47.47
Upside: +135.94%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $68.35
Upside: +75.57%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.37
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.33
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $10.85
Upside: +84.42%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $171.60
Upside: -18.41%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.68
Upside: +317.91%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.68
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.46
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $294.25
Upside: -97.96%